# An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

> **NCT00332917** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 224 (actual)

## Conditions studied

- Early Stage Parkinson's Disease

## Interventions

- **DRUG:** Pardoprunox

## Key facts

- **NCT ID:** NCT00332917
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2009-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332917, "An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00332917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*